vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and INFINITY NATURAL RESOURCES, INC. (INR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $115.5M, roughly 1.5× INFINITY NATURAL RESOURCES, INC.).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESPR vs INR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $115.5M |
| Net Profit | — | $20.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 47.0% |
| Net Margin | — | 17.3% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $115.5M | ||
| Q3 25 | $87.3M | $78.3M | ||
| Q2 25 | $82.4M | $72.5M | ||
| Q1 25 | $65.0M | $84.2M | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | — | ||
| Q2 24 | $73.8M | — | ||
| Q1 24 | $137.7M | — |
| Q4 25 | — | $20.0M | ||
| Q3 25 | $-31.3M | $10.4M | ||
| Q2 25 | $-12.7M | $18.0M | ||
| Q1 25 | $-40.5M | $-34.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | — | ||
| Q2 24 | $-61.9M | — | ||
| Q1 24 | $61.0M | — |
| Q4 25 | 50.6% | 47.0% | ||
| Q3 25 | -11.4% | 30.5% | ||
| Q2 25 | 8.6% | 29.9% | ||
| Q1 25 | -34.0% | -104.5% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | 17.3% | ||
| Q3 25 | -35.9% | 13.3% | ||
| Q2 25 | -15.4% | 24.8% | ||
| Q1 25 | -62.2% | -41.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | — | ||
| Q2 24 | -83.9% | — | ||
| Q1 24 | 44.3% | — |
| Q4 25 | $0.32 | $1.33 | ||
| Q3 25 | $-0.16 | $0.65 | ||
| Q2 25 | $-0.06 | $1.18 | ||
| Q1 25 | $-0.21 | $-2.27 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $2.8M |
| Total DebtLower is stronger | — | $55.0K |
| Stockholders' EquityBook value | $-302.0M | $307.1M |
| Total Assets | $465.9M | $1.2B |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $2.8M | ||
| Q3 25 | $92.4M | $4.6M | ||
| Q2 25 | $86.1M | $6.3M | ||
| Q1 25 | $114.6M | $4.9M | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | — | $55.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $123.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $307.1M | ||
| Q3 25 | $-451.4M | $288.6M | ||
| Q2 25 | $-433.5M | $10.1M | ||
| Q1 25 | $-426.2M | $-52.2M | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | — | ||
| Q2 24 | $-344.2M | — | ||
| Q1 24 | $-294.3M | — |
| Q4 25 | $465.9M | $1.2B | ||
| Q3 25 | $364.0M | $1.1B | ||
| Q2 25 | $347.1M | $1.0B | ||
| Q1 25 | $324.0M | $953.9M | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | — | ||
| Q2 24 | $352.3M | — | ||
| Q1 24 | $373.1M | — |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $75.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.75× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $75.1M | ||
| Q3 25 | $-4.3M | $42.1M | ||
| Q2 25 | $-31.4M | $70.4M | ||
| Q1 25 | $-22.6M | $74.2M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | — | ||
| Q2 24 | $-7.2M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 3.75× | ||
| Q3 25 | — | 4.04× | ||
| Q2 25 | — | 3.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
INR
| Oil Reserves | $54.0M | 47% |
| Natural Gas Reserves | $46.8M | 41% |
| Natural Gas Liquids Reserves | $14.7M | 13% |
